论文部分内容阅读
评价肾骨胶囊治疗血透患者低钙、高磷血症和继发甲旁腺功能亢进的疗效。作者对１４例血透患者进行了肾骨胶囊和安慰剂的交叉试验。结果显示３周内，每天服肾骨胶囊钙（２．０４±０．０９）ｇ，纠正低钙、高磷血症，抑制继发甲状旁腺机能亢进和降低钙磷乘积显著优于安慰剂。经５～８周的随访，虽减少了用药量仍能有效地纠正低钙、高磷血症，血浆全段甲状旁腺激素水平进行性下降。从而证实肾骨胶囊是一种纠正血透患者钙磷代谢紊乱的有效药物。
To evaluate the therapeutic effect of “Shenjian Capsule” on hypocalcemia, hyperphosphatemia and secondary hyperparathyroidism in hemodialysis patients. The authors conducted a crossover trial of kidney capsule with placebo on 14 hemodialysis patients. The results showed that within 3 weeks, taking kidney capsule (2.04 ± 0.09) g, correcting hypocalcemia and hyperphosphatemia, inhibiting secondary hyperparathyroidism and decreasing calcium-phosphorus product was significantly better than placebo . After 5 to 8 weeks of follow-up, although reduced the dosage can still effectively correct hypocalcemia, hyperphosphatemia, plasma parathyroid hormone levels decline. Which confirmed that kidney capsule is a correct hemodialysis patients with calcium and phosphorus metabolism disorders effective drugs.